A Phase 3 interventional study of JW0201 and Placebo in Type 2 Diabetes Mellitus, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment
A multicenter, randomized, double blind, placebo controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2204
A multicenter, randomized, double blind, placebo controlled, parallel, phase Ⅲ study
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's enrollment of 196 is above the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →JW Pharmaceutical is the lead sponsor of 75 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Experimental group, Treatment period for 24 weeks
Drug: JW0201
Placebo group, Treatment period for 24 weeks
Drug: Placebo
JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
Also known as: JW0201+C2022+C2204
C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
Also known as: C2022+C2204
HbA1C (24 Weeks) lowering effect
change in HbA1c
Time frame: 24 Weeks
HbA1c lowering effect
change in HbA1c
Time frame: 6, 12, 18 Weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JW Pharmaceutical